USFDA concludes pre-approval inspection at Visakhapatnam facility of Gland Pharma

25 Feb 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded Pre-approval inspection (PAI) for Sterile APIs at Gland Pharma’s facility at JNPC, Visakhapatnam. The inspection was conducted from February 19, 2025 to February 25, 2025.

The said inspection was concluded with three form 483 observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the USFDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity. 

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1856.80 9.80 (0.53%)
19-Feb-2026 11:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.00
Dr. Reddys Lab 1285.05
Cipla 1350.20
Zydus Lifesciences 910.20
Lupin 2231.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×